불안장애 및 우울증 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Anxiety Disorders and Depression Treatment Market size is expected to reach USD 30.28 Billion in 2034 from USD 20.62 Billion (2025) growing at a CAGR of 4.36% during 2026-2034.

The global anxiety disorders and depression treatment market is growing steadily due to the rising prevalence of mental health conditions worldwide. Anxiety and depression are among the most common mental health disorders, affecting millions of people across different age groups. Increasing awareness about mental health and the importance of early diagnosis has encouraged more individuals to seek professional treatment, including medication, psychotherapy, and digital mental health services.

Several factors are driving the growth of this market, including increasing stress levels, changing lifestyles, and growing social and economic pressures. Healthcare providers are expanding mental health services, while pharmaceutical companies are developing improved antidepressants and anti-anxiety medications with fewer side effects. In addition, telemedicine and online therapy platforms have made mental health treatment more accessible to patients.

In the future, the anxiety disorders and depression treatment market is expected to expand as governments and healthcare organizations invest more in mental health programs. Innovations in digital therapy, personalized treatment approaches, and new drug development are likely to enhance treatment outcomes. Rising awareness and reduced stigma around mental health issues will continue to support market growth in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• Antidepressants
• Anxiolytics
• Anticonvulsants
• Noradrenergic Agents
• Atypical Antipsychotics

By Indication

• Depression
• Anxiety

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

COMPANIES PROFILED

• Pfizer Inc, H Lundbeck AS, GSK plc, Merck Co Inc, Eli Lilly and Company, AstraZeneca, BristolMyers Squibb Company, Johnson Johnson Services Inc, AbbVie Inc, Sanofi
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Antidepressants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Anxiolytics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Anticonvulsants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Noradrenergic Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Atypical Antipsychotics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Depression Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Anxiety Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Type
  • 7.2.2 By Indication
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Type
  • 7.3.2 By Indication
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Type
  • 7.4.2 By Indication
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Type
  • 7.5.2 By Indication
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Type
  • 7.6.2 By Indication
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ANXIETY DISORDERS AND DEPRESSION TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Pfizer Inc
  • 9.2.2 H. Lundbeck A/S
  • 9.2.3 GSK Plc
  • 9.2.4 Merck & Co. Inc
  • 9.2.5 Eli Lilly And Company
  • 9.2.6 AstraZeneca
  • 9.2.7 Bristol-Myers Squibb Company
  • 9.2.8 Johnson & Johnson Services Inc
  • 9.2.9 AbbVie Inc
  • 9.2.10 Sanofi